GO:0097680 double-strand break repair via classical nonhomologous end joining: Mechanism, Genes, Functions and Research Methods
Research-grade guide for scientists and biopharma professionals
Key Takeaways
• GO:0097680 describes the classical nonhomologous end joining (C-NHEJ) pathway that repairs DNA double-strand breaks using KU70/80, DNA-PKcs, XRCC4, and ligase IV, without producing translocations [1,2,3].
• C-NHEJ is the dominant double-strand break repair pathway in mammalian cells and is essential for V(D)J recombination and genome stability.
• The KU70/80 heterodimer initiates C-NHEJ by binding DNA ends, followed by recruitment of DNA-PKcs, XRCC4, XLF, and ligase IV [2,3].
• Defects in C-NHEJ cause radiosensitivity, immunodeficiency, and cancer predisposition; the pathway is also a target for cancer therapy.
• CRISPR/Cas9 genome editing outcomes depend on C-NHEJ, and target residence of Cas9-sgRNA influences repair pathway choice.
• Modeling C-NHEJ in cells and organisms requires knockout, point-mutation, and knock-in strategies to dissect gene function [1,8].
Description
Double-strand breaks (DSBs) are among the most cytotoxic DNA lesions, and their misrepair can lead to mutations, chromosomal rearrangements, and cell death. Cells have evolved multiple DSB repair pathways, including classical nonhomologous end joining (C-NHEJ), which directly ligates broken DNA ends with minimal processing [1,5]. GO:0097680, double-strand break repair via classical nonhomologous end joining, represents the specific biological process that requires factors important for V(D)J recombination, such as the KU70/80 heterodimer, XRCC4, ligase IV, and DNA-PKcs in mammals, and that does not produce translocations, unlike alternative nonhomologous end joining [1,2,3]. This pathway is critical for maintaining genome integrity and for the development of the immune system. Researchers study C-NHEJ to understand its molecular mechanism, its role in disease, and its impact on genome editing outcomes. The pathway is also a target for cancer therapy, as inhibiting C-NHEJ can sensitize tumors to DNA-damaging agents. In this article, we provide a comprehensive overview of GO:0097680, covering its definition, mechanism, key genes, regulation, disease associations, and experimental models for research.
double-strand break repair via classical nonhomologous end joining At A Glance
| GO ID | GO:0097680 |
|---|---|
| GO term | double-strand break repair via classical nonhomologous end joining |
| Ontology | biological_process |
| Synonym | canonical nonhomologous end joining, C-NHEJ |
| Major function | Repair of DNA double-strand breaks by direct ligation of broken ends, requiring KU70/80, DNA-PKcs, XRCC4, and ligase IV, without producing translocations [1,2,3]. |
| Key factors | KU70/80 heterodimer, DNA-PKcs, XRCC4, XLF, ligase IV [2,3]. |
| Associated processes | V(D)J recombination, genome stability, CRISPR/Cas9 genome editing [5,8]. |
| Disease relevance | Radiosensitivity, immunodeficiency, cancer predisposition. |
What Is GO:0097680?
GO:0097680 is defined as an instance of double-strand break repair via nonhomologous end joining that requires a number of factors important for V(D)J recombination, including the KU70/80 heterodimer (KU), XRCC4, ligase IV, and DNA-PKcs in mammals. It does not produce translocations, as opposed to the alternative nonhomologous end joining pathway [1,2,3].
Why Is double-strand break repair via classical nonhomologous end joining Important in Cell Biology?
C-NHEJ is the primary DSB repair pathway in mammalian cells and is essential for maintaining genomic integrity and for V(D)J recombination, which generates immune diversity. Defects in C-NHEJ lead to severe combined immunodeficiency, radiosensitivity, and increased cancer risk. Moreover, C-NHEJ is the dominant repair pathway for CRISPR/Cas9-induced DSBs, directly influencing the outcomes of genome editing experiments. Understanding C-NHEJ is therefore crucial for both basic research and therapeutic applications, including cancer treatment and gene therapy [6,8].
• C-NHEJ is the major DSB repair pathway in mammalian cells, active throughout the cell cycle.
• It is essential for V(D)J recombination, which generates T-cell receptor and immunoglobulin diversity.
• Defects in C-NHEJ cause radiosensitivity, immunodeficiency, and cancer predisposition.
• C-NHEJ determines the outcome of CRISPR/Cas9 genome editing, including insertions and deletions.
• Inhibiting C-NHEJ can sensitize cancer cells to DNA-damaging therapies such as olaparib.
• C-NHEJ is conserved from yeast to humans, with core factors like KU and ligase IV.
• The pathway is a target for drug discovery, with small molecules modulating its activity.
• Studying C-NHEJ provides insights into genome evolution and primate genome stability.
What Happens During double-strand break repair via classical nonhomologous end joining?
DNA End Recognition and KU Binding
In simple terms: The broken DNA ends are recognized and held together by a protein called KU.
The first step in C-NHEJ is the recognition of DNA double-strand breaks by the KU70/80 heterodimer, which forms a ring-like structure that threads onto DNA ends [2,3]. KU binds with high affinity to broken ends, protecting them from degradation and recruiting downstream factors. Structural studies have shown that KU interacts with XLF and that inositol hexaphosphate stabilizes this interaction, stimulating NHEJ. In Arabidopsis, KU mutants are hypersensitive to DSB-inducing agents, confirming its conserved role.
Recruitment of DNA-PKcs and End Processing
In simple terms: A large kinase called DNA-PKcs joins KU at the break to help process the ends.
DNA-PKcs, a member of the phosphatidylinositol 3-kinase-related kinase family, is recruited to KU-bound DNA ends [2,5]. This recruitment activates DNA-PKcs kinase activity, which is important for regulating end processing and ligation. The PAXX protein interacts with KU and is rate-limiting for repair of DSBs requiring end processing, highlighting the complexity of end processing in C-NHEJ. In some cases, end processing involves nucleases such as Artemis, but the core C-NHEJ machinery can ligate compatible ends directly.
Ligation by XRCC4-XLF-Ligase IV Complex
In simple terms: The final step is sealing the break by a ligase complex.
The XRCC4-XLF-ligase IV complex is essential for the ligation step of C-NHEJ [3,5]. XLF interacts with XRCC4 and KU, and this interaction is stimulated by inositol hexaphosphate, which stabilizes the KU-XLF interaction. Ligase IV catalyzes the formation of phosphodiester bonds between the DNA ends. Mutations in XRCC4 or ligase IV cause severe immunodeficiency and radiosensitivity in humans, underscoring their critical role.
Pathway Choice and Avoidance of Translocations
In simple terms: C-NHEJ is precise and avoids joining wrong chromosome ends.
Unlike alternative nonhomologous end joining (alt-NHEJ), which uses microhomology and can produce translocations, C-NHEJ does not produce translocations. The QuickGO definition explicitly states that C-NHEJ does not produce translocations, distinguishing it from alt-NHEJ. This fidelity is crucial for genome stability, as translocations can lead to cancer. The choice between C-NHEJ and other pathways is influenced by factors such as the cell cycle phase and the structure of DNA ends.
Key Genes Involved in GO:0097680 double-strand break repair via classical nonhomologous end joining
The following genes and proteins are core components or regulators of the classical nonhomologous end joining pathway.
| Gene | Major Role | Research Relevance |
|---|---|---|
| XRCC6 (KU70) | Forms KU70/80 heterodimer, binds DNA ends | Knockout causes radiosensitivity and defective V(D)J recombination [1,2] |
| XRCC5 (KU80) | Forms KU70/80 heterodimer, recruits DNA-PKcs | Essential for C-NHEJ; mutations cause immunodeficiency [2,5] |
| PRKDC (DNA-PKcs) | Kinase recruited by KU, regulates end processing | Target for radiosensitization; mutations cause SCID |
| XRCC4 | Scaffold for ligase IV, interacts with XLF | Mutations cause growth retardation and immunodeficiency [3,5] |
| LIG4 | DNA ligase IV, catalyzes ligation | Defects cause LIG4 syndrome, radiosensitivity |
| NHEJ1 (XLF) | Stimulates ligation, interacts with XRCC4 and KU | Mutations cause immunodeficiency with radiosensitivity |
| PAXX | Interacts with KU, promotes end processing | Rate-limiting for repair of complex DSBs |
| DCLRE1C (Artemis) | Nuclease for end processing | Mutations cause SCID with radiosensitivity |
| TP53BP1 | Recruits C-NHEJ factors to breaks | Knockout shifts repair to HR, affects CRISPR outcomes |
| RAD50 | Part of MRN complex, involved in end tethering | Mutations cause Nijmegen breakage syndrome-like |
| MRE11 | Part of MRN complex, end processing | Mutations cause ataxia-telangiectasia-like disorder |
| NBN (Nibrin) | Part of MRN complex, recruits ATM | Mutations cause Nijmegen breakage syndrome |
| ATM | Kinase that coordinates DSB response | Mutations cause ataxia-telangiectasia |
| H2AFX (H2AX) | Histone variant phosphorylated at DSBs | Marker of DSBs, used in research |
| POLM (Pol mu) | Polymerase for filling gaps during C-NHEJ | Knockout affects V(D)J recombination |
| POLL (Pol lambda) | Polymerase for filling gaps during C-NHEJ | Knockout affects V(D)J recombination |
| FEN1 | Flap endonuclease, may process ends | Potential role in C-NHEJ |
| APLF | Aprataxin and PNK-like factor, promotes C-NHEJ | Interacts with XRCC4 and KU |
How Is double-strand break repair via classical nonhomologous end joining Regulated?
C-NHEJ is regulated at multiple levels, including post-translational modifications and protein-protein interactions. Inositol hexaphosphate (IP6) stimulates NHEJ by stabilizing the KU-XLF interaction, as shown by structural and functional studies. The PAXX protein interacts with KU and is rate-limiting for repair of DSBs requiring end processing, indicating that PAXX levels or modifications can regulate pathway efficiency. Additionally, the choice between C-NHEJ and homologous recombination is influenced by cell cycle phase and the target residence of Cas9-sgRNA, which can affect repair outcomes. ATM kinase, a master regulator of the DNA damage response, also modulates C-NHEJ activity through phosphorylation of downstream targets.
double-strand break repair via classical nonhomologous end joining and Human Disease
| Gene | Disease / Biology | Potential Experimental Model |
|---|---|---|
| LIG4 | LIG4 syndrome: immunodeficiency, radiosensitivity | Knockout or point-mutation knock-in in cell lines |
| XRCC4 | Growth retardation, immunodeficiency | Knockout mice or patient-derived iPSCs |
| PRKDC | SCID with radiosensitivity | Knockout in hematopoietic stem cells |
| ATM | Ataxia-telangiectasia | Knockout or point-mutation models |
| FSP1 | Ovarian cancer chemoresistance | Overexpression or knockout in ovarian cancer cells |
Cancer and Chemoresistance
Defects in C-NHEJ can lead to genomic instability and cancer predisposition, but also render cells sensitive to DNA-damaging agents. For example, inhibition of FSP1 enhances olaparib sensitivity in BRCA-proficient ovarian cancer via a nonferroptosis mechanism, highlighting the interplay between DNA repair and cancer therapy. Targeting C-NHEJ components such as DNA-PKcs is a promising strategy to overcome chemoresistance.
Immunodeficiency
C-NHEJ is essential for V(D)J recombination, and mutations in core factors such as KU70/80, DNA-PKcs, XRCC4, ligase IV, and Artemis cause severe combined immunodeficiency (SCID) with radiosensitivity. These disorders underscore the critical role of C-NHEJ in immune system development.
Neurodegeneration
Defective DSB repair, including C-NHEJ, has been linked to neurodegenerative diseases such as ataxia-telangiectasia, which is caused by mutations in ATM. ATM coordinates the DNA damage response, and its loss leads to cerebellar degeneration and cancer predisposition.
Genome Evolution
C-NHEJ and related repair pathways influence genome evolution. Numt-mediated double-strand break repair mitigates deletions during primate genome evolution, suggesting that DSB repair mechanisms shape genome architecture.
From double-strand break repair via classical nonhomologous end joining-Related Genes to Experimental Models
| Research Question | Suitable Model |
|---|---|
| Does gene X promote C-NHEJ? | Knockout cell line (e.g., HEK293T) followed by DSB repair assay |
| Does mutation Y affect C-NHEJ fidelity? | Point-mutation knock-in via CRISPR/Cas9 |
| Where does protein Z localize during C-NHEJ? | Tagged knock-in (e.g., GFP) for live-cell imaging |
| Does overexpression of gene W enhance C-NHEJ? | Overexpression cell line via lentiviral transduction |
| What is the role of gene V in V(D)J recombination? | Knockout mouse model or lymphoid cell lines |
| How does Cas9-sgRNA residence affect repair pathway choice? | CRISPR/Cas9 editing with timed delivery |
How to Study the double-strand break repair via classical nonhomologous end joining Process
| Method | What It Measures | Typical Application |
|---|---|---|
| CRISPR/Cas9 editing | Indel frequency and repair outcomes | Assessing C-NHEJ efficiency in cells |
| EJ5-GFP reporter | C-NHEJ activity | Quantifying repair in knockout cells |
| Cryo-EM | Structural interactions of KU-XLF | Understanding IP6 stimulation |
| Surface plasmon resonance | Binding affinity of PAXX-KU | Determining rate-limiting interactions |
| Immunofluorescence | γH2AX foci formation and resolution | Measuring DSB repair kinetics |
| Next-generation sequencing | Mutation signatures at break sites | Analyzing repair fidelity |
| Comet assay | DNA damage and repair | Assessing radiosensitivity |
| V(D)J recombination assay | Immune receptor diversity | Studying immunodeficiency |
CRISPR/Cas9 Genome Editing to Study C-NHEJ
CRISPR/Cas9 induces site-specific DSBs, and the repair outcomes can be analyzed to infer C-NHEJ activity. By designing sgRNAs and measuring insertions/deletions (indels), researchers can assess the efficiency of C-NHEJ in different genetic backgrounds. Target residence of Cas9-sgRNA influences repair pathway choices, so timing and delivery methods are critical.
DSB Repair Assays
Reporter assays, such as the DR-GFP or EJ5-GFP systems, can specifically measure C-NHEJ activity. These assays use engineered constructs that express GFP only when a DSB is repaired by a specific pathway. In Arabidopsis, such assays have been used to study NHEJ mutants.
Structural Biology and Biophysics
Structural studies, such as X-ray crystallography and cryo-EM, have revealed how KU interacts with XLF and how IP6 stabilizes this interaction. Biophysical techniques like surface plasmon resonance can measure binding affinities between C-NHEJ factors.
Bioinformatics and Genomics
Genomic analyses of repair junctions from CRISPR/Cas9 experiments can reveal the signature of C-NHEJ, such as small indels. Comparative genomics can also identify conserved C-NHEJ factors across species.
How CRISPR Can Be Used to Study GO:0097680 double-strand break repair via classical nonhomologous end joining
Knockout
CRISPR/Cas9 knockout of core C-NHEJ genes such as KU70, KU80, DNA-PKcs, XRCC4, or LIG4 results in cells with defective DSB repair, making them hypersensitive to radiation and other DNA-damaging agents [1,5]. These knockout models are valuable for studying the contribution of each factor to C-NHEJ and for identifying synthetic lethal interactions.
Point Mutation
Introducing point mutations that mimic patient-derived missense mutations (e.g., in LIG4 or XRCC4) allows researchers to dissect the functional impact of specific residues on C-NHEJ activity and to model human immunodeficiency syndromes. Point mutations can also be used to study phosphorylation sites in DNA-PKcs or ATM.
Knock-in
Knock-in of tagged versions of C-NHEJ proteins (e.g., GFP-KU80) enables live-cell imaging of protein dynamics at DSB sites. Knock-in of reporter cassettes, such as the EJ5-GFP reporter, allows quantitative measurement of C-NHEJ activity in a genomic context.
Overexpression
Overexpression of C-NHEJ factors, such as XLF or PAXX, can enhance repair capacity and protect cells from radiation [2,3]. Conversely, overexpression of dominant-negative mutants can inhibit C-NHEJ and sensitize cells to DNA damage. Overexpression models are useful for studying the effects of elevated C-NHEJ on genome stability and cancer.
How EDITGENE Supports double-strand break repair via classical nonhomologous end joining Research
Researchers studying double-strand break repair via classical nonhomologous end joining-related genes often need to determine whether a candidate gene is causally involved in the pathway, how specific mutations affect repair fidelity, and whether modulating its expression alters cellular sensitivity to DNA damage. EDITGENE provides a comprehensive suite of CRISPR-based services to address these questions, from gene knockout to precise point mutations and knock-in reporters.
Contact EDITGENE today to design your custom CRISPR model for double-strand break repair via classical nonhomologous end joining research.
Frequently Asked Questions About double-strand break repair via classical nonhomologous end joining
What is GO:0097680?
GO:0097680 is the Gene Ontology term for double-strand break repair via classical nonhomologous end joining, a biological process that repairs DNA double-strand breaks using factors like KU70/80, DNA-PKcs, XRCC4, and ligase IV, without producing translocations [1,2,3].
What genes are involved in classical nonhomologous end joining?
Core genes include XRCC6 (KU70), XRCC5 (KU80), PRKDC (DNA-PKcs), XRCC4, LIG4, NHEJ1 (XLF), and PAXX, among others [2,3,5].
How does classical nonhomologous end joining work?
The KU70/80 heterodimer binds DNA ends, recruits DNA-PKcs, and then the XRCC4-XLF-ligase IV complex ligates the ends, often with minimal processing [2,3,5].
What is the difference between classical and alternative nonhomologous end joining?
Classical NHEJ (C-NHEJ) requires KU, DNA-PKcs, XRCC4, and ligase IV and does not produce translocations, while alternative NHEJ uses microhomology and can cause translocations.
Why is classical nonhomologous end joining important for CRISPR/Cas9?
CRISPR/Cas9 induces double-strand breaks that are predominantly repaired by C-NHEJ, leading to insertions or deletions that can disrupt gene function.
What diseases are associated with defects in classical nonhomologous end joining?
Defects cause severe combined immunodeficiency, radiosensitivity, and cancer predisposition, as seen in LIG4 syndrome and other disorders [5,6].
How can I study classical nonhomologous end joining in the lab?
Common methods include CRISPR/Cas9 editing, reporter assays like EJ5-GFP, immunofluorescence for γH2AX, and structural biology techniques [1,3,8].
What is the role of KU70/80 in classical nonhomologous end joining?
KU70/80 forms a heterodimer that binds DNA ends, protects them, and recruits downstream factors such as DNA-PKcs and XLF [2,3].
Can classical nonhomologous end joining be inhibited for cancer therapy?
Yes, inhibitors of DNA-PKcs and other C-NHEJ factors are being developed to sensitize cancer cells to radiation and chemotherapy.
What model systems are used to study classical nonhomologous end joining?
Models include knockout cell lines, mouse models, and Arabidopsis mutants, as well as patient-derived cells with mutations in C-NHEJ genes [1,5].
Conclusion
Classical nonhomologous end joining (GO:0097680) is a fundamental DNA repair pathway that safeguards genome integrity and is essential for immune development. Its core factors, including KU70/80, DNA-PKcs, XRCC4, and ligase IV, are conserved and tightly regulated [1,2,3,5]. Defects in C-NHEJ lead to immunodeficiency, radiosensitivity, and cancer, making it a key target for therapeutic intervention [5,6]. Moreover, C-NHEJ dictates the outcomes of CRISPR/Cas9 genome editing, underscoring its importance in modern biotechnology. Continued research into C-NHEJ mechanisms, regulation, and disease connections will advance both basic science and clinical applications.
References
- 1. Shen H et al.. 2017. CRISPR/Cas9-Induced Double-Strand Break Repair in Arabidopsis Nonhomologous End-Joining Mutants.. G3 (Bethesda) 7(1):193-202 PMID: 27866150
- 2. Gluza J et al.. 2025. PAXX/Ku interaction is rate limiting for repair of double-strand DNA breaks requiring end processing.. J Biol Chem 301(8):110481 PMID: 40659092
- 3. Kefala Stavridi A et al.. 2023. Structural and functional basis of inositol hexaphosphate stimulation of NHEJ through stabilization of Ku-XLF interaction.. Nucleic Acids Res 51(21):11732-11747 PMID: 37870477
- 4. Seol JH et al.. 2018. Microhomology-mediated end joining: Good, bad and ugly.. Mutat Res 809:81-87 PMID: 28754468
- 5. Iliakis G et al.. 2004. Mechanisms of DNA double strand break repair and chromosome aberration formation.. Cytogenet Genome Res 104(1-4):14-20 PMID: 15162010
- 6. Miao H et al.. 2024. FSP1 inhibition enhances olaparib sensitivity in BRCA-proficient ovarian cancer patients via a nonferroptosis mechanism.. Cell Death Differ 31(4):497-510 PMID: 38374229
- 7. Hazkani-Covo E et al.. 2008. Numt-mediated double-strand break repair mitigates deletions during primate genome evolution.. PLoS Genet 4(10):e1000237 PMID: 18949041
- 8. Liu SC et al.. 2022. Target residence of Cas9-sgRNA influences DNA double-strand break repair pathway choices in CRISPR/Cas9 genome editing.. Genome Biol 23(1):165 PMID: 35915475
